Raised $100M Series A extended ($60M + $40M add-on after clinical data) from Atlas, Frazier, Access Industries. Only oral drug in development for isolated dystonia. Phase 2 in dystonia and Parkinson's in 2026.
Vima Therapeutics is developing VIM0423, the only oral drug in clinical development for isolated dystonia — a movement disorder characterized by involuntary, sustained muscle contractions affecting approximately 160,000 people in the US, with zero FDA-approved oral treatment options. The company raised a $100 million Series A (extended from $60 million to $100 million after positive clinical data) from Atlas Venture, Frazier Life Sciences, and Access Industries. VIM0423 is entering Phase 2 trials in both isolated dystonia and Parkinson's disease tremor in 2026.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.